{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-039898","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-08-24T21:13:36+00:00","discovered_at":"2026-08-24T21:14:04.726012+00:00","generated_at":"2026-08-24T21:14:23.174496+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ensyce raises $21M initial tranche of $43M Series C financing; Nasdaq compliance update","bullets":["Initial closing Aug 7, 2026 raised >$21M gross; issued 120,260 Series C preferred shares.","Two-tranche $43M Securities Purchase Agreement; second tranche closes on clinical milestone.","Company believes it satisfies Nasdaq's $2.5M minimum stockholders' equity (Rule 5550(b)(1)).","Requested Aug 24, 2026 for second 180-day grace period on $1.00 bid price rule (equity >=$5M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-039898","json":"https://secwatch.observer/filing/0001493152-26-039898.json","markdown":"https://secwatch.observer/filing/0001493152-26-039898.md","text":"https://secwatch.observer/filing/0001493152-26-039898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226039898/0001493152-26-039898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226039898/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-24T21:14:23.174496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}